Volume 6 Supplement 2

Frontiers of Retrovirology: Complex retroviruses, retroelements and their hosts

Open Access

Replication kinetics and persistence of a conditionally live attenuated SIV (SIVrtTA) in vivo confers protection against SIVmac239 wild-type challenge in a rhesus macaque model

  • Neil Berry1,
  • Atze Das2,
  • Mark Page1,
  • Hannah Tudor1,
  • Mark Robinson1,
  • Ruby Quartey-Papafio1,
  • William Elsley1,
  • Deborah Ferguson1,
  • Bo Li1,
  • Wendy Kleibeuker2,
  • Bep Klaver2,
  • Maria Manoussaka3,
  • Richard Stebbings1,
  • Martin Cranage3,
  • Ben Berkhout2 and
  • Neil Almond1
Retrovirology20096(Suppl 2):P13

DOI: 10.1186/1742-4690-6-S2-P13

Published: 24 September 2009

Vaccination with live attenuated SIV confers potent protection against wild-type SIV challenge in the SIV/macaque model of HIV. Although safety concerns preclude the direct application of this vaccine approach in humans, a clearer understanding of its mechanism of protection may lead to the development of novel AIDS vaccines. A novel live attenuated SIVmac239 Δnef vaccine (SIVrtTA), dependent on doxycycline administration for replication, has been evaluated in vivo and its ability to protect against pathogenic SIV challenge determined. Two groups of six Indian rhesus macaques (Groups A and B) were vaccinated with SIVrtTA with an oral doxycycline dosing regime for 6 months. In Group A, doxycycline was stopped for 8 weeks before wtSIVmac239 challenge. A third group was vaccinated with a conventional SIVmac239Δnef vaccine. In the presence of doxycycline, all 12 macaques receiving SIVrtTA were infected exhibiting peak SIV RNA levels (log10 3-5 SIV RNA copies/ml) which declined in all macaques but persisted at higher levels in three SIVrtTA vaccinates. Levels of virus replication measured by independent qRT-PCR and qDNA PCR assays were lower in SIVrtTA vaccinates compared with the SIVmac239Δnef vaccine which peaked in the log10 4-6 SIV RNA copies/ml range. No escape from doxycycline dependence was identified. Upon challenge with wild-type SIVmac239 and compared with naive challenge controls (Group D), a significant vaccine effect was observed in all three vaccine groups, assessed by the comparative reduction of circulating viral RNA in plasma. Naive wtSIVmac239 challenge controls exhibited ~7 log10 SIV RNA copies/ml at peak which persisted beyond the acute infection phase. This compared with all three vaccine groups where post wtSIVmac239 viral RNA levels were markedly reduced among SIVrtTA vaccinates with a more pronounced vaccine effect among Group A vaccinates. Viral RNA was un-detectable in one SIVrtTA vaccinate (Group A) and in the 2 log10 range in another (Group B). The highest levels of protection in SIVrtTA vaccinates correlated with an enhanced persistence of SIVrtTA as circulating viral RNA in the immediate post-acute infection vaccine period. Retrospective sequence analysis recovered from SIVrtTA vaccinates indicated a selection of sequence variants in the LTR promoter region and the Tat and rtTA genes that do not affect doxycycline control but which may have influenced replication in vivo. Vaccination with SIVrtTA induced a marked vaccine effect which will enable the role of viral persistence to be evaluated in this vaccination strategy. SIVrtTA represents a new tool to develop and design novel AIDS vaccines.

Authors’ Affiliations

(1)
NIBSC, Division of Retrovirology, Health Protection Agency
(2)
Laboratory of Experimental Virology, Department of Medical Microbiology, Center for Infection and Immunity Amsterdam (CINIMA), Academic Medical Center of the University of Amsterdam
(3)
Division of Cellular and Molecular Medicine, St. George's University of London

Copyright

© Berry et al; licensee BioMed Central Ltd. 2009

This article is published under license to BioMed Central Ltd.

Advertisement